These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28466574)

  • 1. Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis.
    Liu G; Xu P; Fu Z; Hua X; Liu X; Li W; Zhang M; Wu J; Wen J; Xu J; Jia X
    J Cell Biochem; 2017 Dec; 118(12):4517-4525. PubMed ID: 28466574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
    Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
    Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
    Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.
    Kelemen LE; Rambau PF; Koziak JM; Steed H; Köbel M
    Cancer Causes Control; 2017 May; 28(5):447-457. PubMed ID: 28194593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
    Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
    Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients.
    Kato MK; Yoshida H; Tanase Y; Uno M; Ishikawa M; Kato T
    Pathol Oncol Res; 2021; 27():598550. PubMed ID: 34257552
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
    Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
    J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
    Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
    Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
    Lowery WJ; Schildkraut JM; Akushevich L; Bentley R; Marks JR; Huntsman D; Berchuck A
    Int J Gynecol Cancer; 2012 Jan; 22(1):9-14. PubMed ID: 22193641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer.
    Srdelić S; Kuzmić-Prusac I; Spagnoli GC; Juretić A; Čapkun V
    Int J Gynecol Pathol; 2019 Jan; 38(1):59-65. PubMed ID: 29140883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
    Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J
    Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.
    Maeda D; Mao TL; Fukayama M; Nakagawa S; Yano T; Taketani Y; Shih IeM
    Int J Mol Sci; 2010; 11(12):5120-8. PubMed ID: 21614196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
    Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
    Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
    Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
    Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.